Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and SABR in Oligometastatic Head and Neck Squamous Cell Carcinoma
NCT05815927Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- May 2025
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival at 2.6 years. Started May 2025; status: recruiting.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05815927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815927.